RPG Life Sciences Limited , a leading integrated pharmaceutical company, has announced its strategic focus on expanding its international formulations and Active Pharmaceutical Ingredient (API) business, alongside reporting a steady financial performance for the first quarter.

Strategic Expansion

The company's co-executive has confirmed RPG Life's commitment to strengthening its global presence in the formulations and API sectors. This expansion strategy encompasses:

• Attracting new clients
• Entering new markets
• Introducing new molecules to broaden treatment options

This move aligns with RPG Life Sciences' vision to establish a stronger foothold in the international pharmaceutical landscape.

Q1 Financial Highlights

For the quarter ended June 30, RPG Life Sciences reported:

The company maintained a healthy EBITDA margin of 24.1%, despite a slight decrease from the previous year. The profit before tax remained largely in line with the previous year's figure.

Segment-wise Performance

• Domestic Formulations: Contributed 69% to total sales, delivering market-beating growth.
• International Formulations: Accounted for 19% of total sales, with improving contributions from new products, customers, and markets.
• API Business: Represented 12% of total sales, with growth impacted by a fire incident in one of the manufacturing blocks.

Management Commentary

Mr. Ashok Nair, Managing Director of RPG Life Sciences Ltd., commented on the results: "In Q1, we have sustained our sales growth momentum, reflecting the strength of our strategic execution and operational excellence. Our Domestic Formulations business continues to deliver market-beating growth, propelled by a focused transformation agenda and a customer-centric approach."

He further added, "We remain firmly on track to accelerate both our International Formulations and API segments, with growth driven by rapid onboarding of new customers, strategic expansion into newer markets, and launch of newer molecules that broaden our therapeutic reach."

Future Outlook

RPG Life Sciences is actively exploring inorganic growth opportunities across both formulations and APIs to accelerate its growth trajectory. The company's strategy includes:

1. Focusing on new geographies and expanding the product launch pipeline
2. Strengthening customer relationships and onboarding high-value clients
3. Implementing digital initiatives to streamline operations
4. Evaluating M&A opportunities in target therapies and brands
5. Developing a focused new product pipeline across segments and therapies

Leadership Appointment

In a move to strengthen its API business, RPG Life Sciences has appointed Mr. Deepak Shukla as Chief Executive - API Business, effective July 28. Mr. Shukla brings with him about 25 years of experience in the pharmaceutical industry, having worked with reputed companies such as UPL Group, Teva Group, and Dr. Reddy's Laboratories.

As RPG Life Sciences continues to expand its global footprint and diversify its product portfolio, the company remains committed to delivering quality, affordable medicines while creating value for all stakeholders.

RPG Life Sciences Limited , a leading integrated pharmaceutical company, has announced its financial results for the first quarter of fiscal year 2026 and made a key appointment to strengthen its API business.

Q1 FY26 Financial Highlights

The company reported a modest growth in revenue for the quarter ended June 30, 2025:

Despite the challenging environment, RPG Life Sciences maintained a healthy EBITDA margin of 24.1% and saw a slight improvement in its PAT margin.

Segment-wise Performance

• Domestic Formulations: This segment, contributing 69% to total sales, showed strong growth of 9.5% year-on-year, reaching ₹115.50 crores.
• International Formulations: Contributing 19% to total sales, this segment experienced a slight decline of 2.7%, with revenues of ₹32.50 crores.
• API Business: The API segment, accounting for 12% of total sales, saw a significant decline of 22.4% due to a fire incident in one of the manufacturing blocks, with revenues of ₹19.60 crores.

Strategic Appointment

In a move to bolster its API business, RPG Life Sciences has appointed Mr. Deepak Shukla as Chief Executive - API Business, effective July 28, 2025. Mr. Shukla brings with him approximately 25 years of experience in the pharmaceutical industry, having worked with renowned companies such as UPL Group, Teva Group, AkzoNobel India, Ranbaxy Laboratories, and Dr. Reddy's Laboratories.

Management Commentary

Mr. Ashok Nair, Managing Director of RPG Life Sciences Ltd., commented on the results, stating, "In Q1, we have sustained our sales growth momentum, reflecting the strength of our strategic execution and operational excellence. Our Domestic Formulations business continues to deliver market-beating growth, propelled by a focused transformation agenda and a customer-centric approach."

He further added, "We remain firmly on track to accelerate both our International Formulations and API segments, with growth driven by rapid onboarding of new customers, strategic expansion into newer markets, and launch of newer molecules that broaden our therapeutic reach."

Future Outlook

The company is actively exploring inorganic growth opportunities across both formulations and APIs to accelerate its growth trajectory. With a strong focus on new product development, market expansion, and operational efficiency, RPG Life Sciences aims to create lasting value for all stakeholders.

The Board of Directors has also approved a revision in the policy for Determination of Materiality of Events in accordance with amended SEBI regulations, underlining the company's commitment to transparency and corporate governance.

As RPG Life Sciences continues to navigate the dynamic pharmaceutical landscape, its strategic initiatives and focus on core business segments position it well for future growth and market expansion.